TRANS GENIC AND KUMAMOTO FOUNDATION CONCLUDE ANTI-HIV ANTIBODY LICENSE

Trans Genic, a biotech company specializing in genome function research, and the Kumamoto Techno Industrial foundation have concluded an exclusive license agreement on anti-HIV antibodies PCT/JP2004/003046. The partners have produced a monoclonal antibody with a high level of neutralization activity against HIV as part of a therapeutic drug for AIDS.

Pipeline Review (http://www.pipelinereview.com/joomla/content/view/5268/118/)